* Tempest Therapeutics Inc is expected to show no change in quarterly revenue when it reports results on March 20 (estimated) for the period ending December 31 2023
*
* LSEG's mean analyst estimate for Tempest Therapeutics Inc is for a loss of 39 cents per share.
* The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 6 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in the last three months.
* Wall Street's median 12-month price target for Tempest Therapeutics Inc is $13.00, above its last closing price of $3.64.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Sep. 30 2023 -0.56 -0.57 -0.48 Beat 16.2
Jun. 30 2023 -0.55 -0.52 -0.54 Missed -4.3
Mar. 31 2023 -0.65 -0.64 -0.55 Beat 14.4
Dec. 31 2022 -0.76 -0.63 Beat 17
Sep. -0.81 -0.80 -0.66 Beat 17.8
30 2022
Jun. 30 2022 -0.93 -0.92 -0.79 Beat 14.4
Mar. 31 2022 -1.12 -1.12 -1.18 Missed -5.7
Dec. 31 2021 -1.23 -1.12 Beat 9.1
This summary was machine generated March 18 at 11:02 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments